You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for AVP-786


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug AVP-786?

AVP-786 is an investigational drug.

There have been 17 clinical trials for AVP-786. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Psychomotor Agitation, Dementia, and Alzheimer Disease. The leading clinical trial sponsors are Avanir Pharmaceuticals and [disabled in preview].

There are eighty-one US patents protecting this investigational drug and one hundred and seventy-two international patents.

Recent Clinical Trials for AVP-786
TitleSponsorPhase
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAvanir PharmaceuticalsPhase 3
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAvanir PharmaceuticalsPhase 3
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaAvanir PharmaceuticalsPhase 2/Phase 3

See all AVP-786 clinical trials

Clinical Trial Summary for AVP-786

Top disease conditions for AVP-786
trials01234567Psychomotor AgitationDementiaAlzheimer DiseaseSchizophrenia[disabled in preview]
Top clinical trial sponsors for AVP-786
trials024681012141618Avanir Pharmaceuticals[disabled in preview]

See all AVP-786 clinical trials

US Patents for AVP-786

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
AVP-786 ⤷  Subscribe Bupropion as a modulator of drug activity ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Bupropion as a modulator of drug activity ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
AVP-786 ⤷  Subscribe Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 7 of 7 entries

International Patents for AVP-786

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
AVP-786 Australia AU2014346807 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2015350559 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2018203638 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2019201548 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2019223187 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2019236614 2033-11-05 ⤷  Subscribe
AVP-786 Australia AU2019275593 2033-11-05 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 7 of 7 entries

Development Update and Market Projection for AVP-786

Introduction to AVP-786

AVP-786, a drug candidate developed by Avanir Pharmaceuticals in collaboration with Concert Pharmaceuticals, was designed to treat agitation associated with dementia due to Alzheimer's disease. This compound is a deuterium-modified form of dextromethorphan, combined with quinidine sulfate, aiming to improve pharmacokinetic properties without altering its mechanism of action[1][4].

Development History

Early Clinical Trials

The clinical development of AVP-786 began in October 2012 with a Phase 1 trial involving 48 young, healthy volunteers to test the safety, tolerability, and pharmacokinetics of deuterated dextromethorphan. Subsequent Phase 1 trials were conducted in 2013 and early 2015, including comparisons with its predecessor AVP-923 and interactions with other medications[1].

Phase 3 Trials and FDA Fast-Track Designation

In November 2015, the FDA granted AVP-786 fast-track designation for the treatment of agitation associated with Alzheimer's disease. However, the TRIAD-2 study in 2019 reported negative results, showing no improvement in agitation compared to placebo. Despite this, Avanir continued with additional Phase 3 trials initiated in 2020, involving 750 participants each, to further evaluate the drug's efficacy[1][3].

Recent Developments and Termination

Phase 3 Topline Results

In February 2024, Otsuka Pharmaceutical Co., Ltd. announced the topline results of the Phase 3 trial (Trial 17-AVP-786-305; NCT03393520), which failed to show a statistically significant difference between AVP-786 and placebo in the primary efficacy endpoint, the mean change from baseline to week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score. Adverse events included falls, urinary tract infections, and somnolence, but no deaths were attributed to AVP-786[3][5].

Termination of Development

Following the disappointing results, Otsuka decided to terminate the development of AVP-786 for the treatment of agitation associated with dementia due to Alzheimer's disease. This decision was made after a detailed analysis of the trial results, despite initial plans to continue further analyses and potential submissions for scientific publication[5].

Market Implications

Current Market Landscape

The global Alzheimer's disease treatment market is projected to grow significantly from 2024 to 2031, driven by the increasing prevalence of Alzheimer's disease and the need for effective treatments. However, the termination of AVP-786 development removes a potential contender from this market[2].

Impact on Alzheimer's Treatment Market

The failure of AVP-786 to demonstrate efficacy in treating agitation associated with Alzheimer's disease highlights the challenges in developing effective treatments for this condition. Agitation is a common and debilitating symptom affecting approximately half of all patients with Alzheimer's dementia, significantly impacting the quality of life for patients, family members, and caregivers. The absence of AVP-786 from the market means that other treatments will need to fill this gap, potentially increasing the demand for existing or emerging therapies[3].

Future Directions

Alternative Treatments

Given the unmet need for effective treatments for agitation in Alzheimer's disease, pharmaceutical companies are likely to continue investing in research and development of new therapies. The recent approval of other drugs for this patient population, as mentioned by Otsuka, indicates ongoing innovation in this area[3].

Lessons Learned

The development and termination of AVP-786 provide valuable insights into the complexities of drug development, particularly for neurological conditions. The use of deuterium chemistry, while promising in terms of pharmacokinetic improvements, did not translate into clinical efficacy in this case. This experience can inform future drug development strategies and highlight the importance of robust clinical trials[1][4].

Key Takeaways

  • Development Termination: AVP-786's development was terminated due to the failure to demonstrate efficacy in Phase 3 trials.
  • Market Impact: The termination affects the Alzheimer's disease treatment market, which continues to grow but lacks effective treatments for agitation.
  • Future Directions: Pharmaceutical companies will continue to seek alternative treatments to address the unmet needs in Alzheimer's disease.
  • Lessons Learned: The experience with AVP-786 underscores the challenges and complexities of drug development for neurological conditions.

FAQs

  1. What was AVP-786 intended to treat? AVP-786 was intended to treat agitation associated with dementia due to Alzheimer's disease.

  2. Why was the development of AVP-786 terminated? The development was terminated due to the failure to show a statistically significant difference between AVP-786 and placebo in the primary efficacy endpoint in Phase 3 trials.

  3. What is the significance of deuterium chemistry in AVP-786? Deuterium chemistry was used to modify dextromethorphan, aiming to improve its pharmacokinetic properties without changing its mechanism of action.

  4. How common is agitation in Alzheimer's disease? Agitation is reported in approximately half of all patients with Alzheimer's dementia and significantly impacts their quality of life and that of their caregivers.

  5. What are the implications for the Alzheimer's treatment market? The termination of AVP-786 development means that other treatments will need to fill the gap, potentially increasing demand for existing or emerging therapies.

Sources

  1. AVP-786 | ALZFORUM https://www.alzforum.org/therapeutics/avp-786

  2. Alzheimer's Disease Treatment Market and Forecast 2024-2031 https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/

  3. Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease https://www.otsuka.co.jp/en/company/newsreleases/2024/20240213_1.html

  4. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next-Generation Compound AVP-786 https://www.prnewswire.com/news-releases/avanir-pharmaceuticals-announces-positive-interim-data-from-pharmacokinetic-study-with-next-generation-compound-avp-786-190182801.html

  5. Otsuka to Terminate Development of AVP-786 https://otsuka-us.com/news/otsuka-terminate-development-avp-786

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.